Early Parkinsonism in a Senegalese girl with Lafora disease.
»
Early Parkinsonism in a Senegalese girl with Lafora disease.
We report an atypical presentation LaFora disease in a Senegalese girl carrying homozygous variant, c.560A> C, in the gene NHLRC1. At 13 years, patients developed myoclonic seizures and visual, progressive psychomotor slowing, and cognitive decline. At 14 years old, showed severe neurological examination hypomimia, bradykinesia, rigidity and low-amplitude myoclonic jerks. Flash-visual and somatosensory potential arouse shows the amplitude increase of cortical component, while electroretinogram showed attenuated responses.
EEG showed diffuse polyspikes associated with positive-negative jerks and posterior slow waves and spikes irregularly. Figure electroclinical suggest the diagnosis of diseases of the association LaFora visual seizures, cognitive decline, and myoclonus action, together with the EEG and generate potential findings. Two rare findings were superiority extrapyramidal signs in the early stages of the disease (which is rarely reported) and damping responses electroretinal. We assume that LaFora disease diagnosis must be included in the work-up for teens Parkinsonism, when associated with epilepsy.
LaFora disease is a rare, genetic, metabolic disorder is inherited as an autosomal recessive glycogen which is characterized by inclusion bodies, known as LaFora body, in the cytoplasm of cells in the heart, liver, muscles, and skin. LaFora disease presents as a neurodegenerative disorder that causes disruption in the development of cerebral cortical neurons.
We present here the case of illness LaFora presented with progressive myoclonus epilepsy (PME) and investigated at our center. She was diagnosed as having the disease LaFora with typical histologic findings in the skin biopsy and found to be positive for pathogenic mutations in genetic testing.
Early Parkinsonism in a Senegalese girl with Lafora disease.
The 5th International LaFora Epilepsy Workshop: Science elucidating the basis of therapeutic options and prepare for therapy in the clinic.
LaFora disease (LD) is a fatal epilepsy in children and glycogen storage disease caused by recessive mutations in both the progressive myoclonus epilepsy 2A (EPM2A) or gene EPM2B.
The advantages of LD aberrant carbohydrate cytoplasmic aggregates called LaFora body (LBS) which is a driver of the disease. The LaFora Epilepsy 5th International Workshop recently held in Alcala de Henares, Spain. The workshop was attended by nearly 100 doctors, academic and industrial scientists, trainees, National Institutes of Health (NIH) representation, and friends and family members of patients with LD. The workshop covers aspects ranging from defining LD basic scientific mechanism for elucidating the LD or healing therapies and natural history studies recently launched LD.
LaFora disease is a rare, genetic, metabolic disorder is inherited as an autosomal recessive glycogen which is characterized by inclusion bodies, known as LaFora body, in the cytoplasm of cells in the heart, liver, muscles, and skin. LaFora disease presents as a neurodegenerative disorder that causes disruption in the development of cerebral cortical neurons.
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.
NOVATest IgG/IgM Antibody Rapid Test Kit (NOVA Test)
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again.
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.
NOVATest Antigen Rapid Test Kit (For Single Use) (NOVA Test)
Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended.
Description: The product is a lateral flow chromatographic immunoassay for the qualitative detection of monkeypox virus antigen in human whole blood, serum, plasma or rash exuudate. The kit is intended for professional use only.
Human Coxsackievirus group B (CVB) IgM Rapid Test Kit
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications.
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19
We present here the case of illness LaFora presented with progressive myoclonus epilepsy (PME) and investigated at our center. She was diagnosed as having the disease LaFora with typical histologic findings in the skin biopsy and found to be positive for pathogenic mutations in genetic testing.
